MorphoSys AG (MOR) 2015年年度报告「NASDAQ」.pdf

1、Annual Report 2015Engineering the Medicinesof Tomorrow Product PipelineMorphoSyss Product Pipeline,as of December 31,2015MOST ADVANCED DEVELOPMENT STAGEPROGRAM/PARTNER INDICATIONBimagrumab/BYM338(Novartis)sIBM(musculoskeletal)Guselkumab/CNTO1959(Janssen/J&J)Psoriasis Gantenerumab(Roche)Alzheimers di

2、sease MOR208(not partnered)CLL,NHL MOR202(not partnered)Multiple myeloma MOR103/GSK3196165(GlaxoSmithKline)Rheumatoid Arthritis(RA)Anetumab Ravtansine/BAY94-9343(Bayer)Mesothelioma BHQ880(Novartis)Multiple myeloma BPS804(Mereo/Novartis)Brittle bone syndrome CNTO3157(Janssen/J&J)Infl ammation CNTO678

3、5(Janssen/J&J)Infl ammation LFG316(Novartis)Eye diseases LJM716(Novartis)Cancer Tarextumab/OMP-59R5(OncoMed)Solid tumors VAY736(Novartis)Infl ammation MOR209/ES414(Emergent)Prostate cancer LEGEND:mor program out-licensed mor program partnered discovery programMOST ADVANCED DEVELOPMENT STAGEPROGRAM/P

4、ARTNER INDICATIONBAY1093884(Bayer)Hemophilia BI-836845(BI)Solid tumors NOV-7(Novartis)Eye diseases NOV-8(Novartis)Infl ammation NOV-9(Novartis)Diabetic eye diseases NOV-10(Novartis)Cancer NOV-11(Novartis)Blood disorders PF-05082566(Pfi zer)Solid tumors Vantictumab/OMP-18R5(OncoMed)Solid tumors MOR10

5、6(Galapagos)Infl ammation MOR107/LP2(not partnered)Fibrosis 25 partnered programs Various Immuno-oncology program(Merck Serono)Cancer Immuno-oncology program(Immatics)Cancer 6 MOR programs Various 43 partnered programs Various DISCOVERYPRECLINICPHASE 1PHASE 2PHASE 3MARKETDISCOVERYPRECLINICPHASE 1PHA

6、SE 2PHASE 3MARKET103Programs in Total1 Out-licensed Program89 Partnered Discovery Programs13 Proprietary ProgramsIn addition,8 proprietary programs and 43 partnered discovery programs are in discovery stage,2 proprietary and 25 partnered discovery programs are in preclinic.25Clinical Product Candida